Last reviewed · How we verify

dexmedetomidine combined with remifentanil

Nanjing First Hospital, Nanjing Medical University · Phase 1 active Small molecule Quality 0/100

dexmedetomidine combined with remifentanil is a Small molecule drug developed by Nanjing First Hospital, Nanjing Medical University. It is currently in Phase 1 development. Also known as: dexmedetomidine-remifentanil.

At a glance

Generic namedexmedetomidine combined with remifentanil
Also known asdexmedetomidine-remifentanil
SponsorNanjing First Hospital, Nanjing Medical University
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about dexmedetomidine combined with remifentanil

What is dexmedetomidine combined with remifentanil?

dexmedetomidine combined with remifentanil is a Small molecule drug developed by Nanjing First Hospital, Nanjing Medical University.

Who makes dexmedetomidine combined with remifentanil?

dexmedetomidine combined with remifentanil is developed by Nanjing First Hospital, Nanjing Medical University (see full Nanjing First Hospital, Nanjing Medical University pipeline at /company/nanjing-first-hospital-nanjing-medical-university).

Is dexmedetomidine combined with remifentanil also known as anything else?

dexmedetomidine combined with remifentanil is also known as dexmedetomidine-remifentanil.

What development phase is dexmedetomidine combined with remifentanil in?

dexmedetomidine combined with remifentanil is in Phase 1.

Related